UNLIMITED TURBO BULL - NOVO-NORDISK B | Real-time Euronext Paris 06:34:13 23/05/2024 pm IST | ||
| 6.17 EUR | +3.35% |
|
| Current month | +6.61% | ||
| 1 month | +10.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 6.17 | +3.35% |
| 22/24/22 | 5.97 | -0.33% |
| 21/24/21 | 5.99 | +3.10% |
| 20/24/20 | 5.81 | +1.75% |
| 17/24/17 | 5.71 | -2.56% |
Real-time Euronext Paris
Last update May 23, 2024 at 06:34 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 566MS | |
| ISIN | DE000SV2Q6H4 |
| Date issued | 28/03/2023 |
| Strike | 479.3 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.41 € |
|---|---|
| Lowest since issue | 0.695 € |
| Spread | 0.01 € |
| Spread % | 0.16% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- 566MS Certificat
